SK bioscience Co.,Ltd.

A302440

KR7302440003

SK Bioscience Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biological products. The Company's main products include vaccines such as SKYCellflu and Rotatech. The Company also sells infusion solutions. In addition, the Company engages in technology export business. The Company sells its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for SK bioscience Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

57,400 KRW

Average target price

58,000 KRW

Spread / Average Target

+1.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SK BIOSCIENCE CO.,LTD.	-20.28%	3.2B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
57,400 ^KRW	-0.17%		0.00%	-20.28%

Mar. 28	SK Bioscience Signs Deal with Sanofi for Five Vaccine Types	MT
Mar. 07	SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline	CI

SK Bioscience Signs Deal with Sanofi for Five Vaccine Types	Mar. 28	MT
SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline	Mar. 07	CI
SK Bioscience Obtains Prequalification Certification from the World Health Organization	Feb. 23	CI
SK Bioscience's Net Income Plunges in Q4	Feb. 02	MT
SK Bioscience to Expand Facilities to Develop New Pneumococcal Vaccine	Nov. 30	MT
SK Group Advances Net Zero Transition via Key Renewable Energy Deal	Nov. 27	MT
SK Bioscience, Hilleman Laboratories Partner on Second-Gen Ebola Virus Vaccine	Nov. 22	MT
SK Bioscience Partners with Australian Company to Collaborate on Patch-Type Typhoid Vaccine Development	23-08-25	MT
SK Bioscience Set to Deliver 5 Million Doses of Innovative Cell-Based Flu Vaccine SKYCellflu	23-08-23	MT
SK Bioscience Boosts Partnership with Novavax via Acquisition of 6.5 Million Shares	23-08-10	MT
Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.	23-08-07	CI
S.Korean shares hit 14-month high on platform, biopharma boost	23-07-31	RE
SK Bioscience Swings to Loss in Q2	23-07-31	MT
S.Korean shares end flat in wait-and-see mood; earnings, Fed in focus	23-07-19	RE
SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate	23-06-29	CI
South Korean Stocks Close Flat After Fed Rate Hike; SK Bioscience Rises 16%	23-05-04	MT
SK Bioscience Swings to Loss in Q1; Shares Jump 15%	23-05-03	MT
SK Bioscience Allots 2.4 Trillion Won for Contract Manufacturing Business	23-05-01	MT
SK Bioscience Swings to Loss in Q1	23-04-28	MT
SK Bioscience Rallies After Clinical Trials of Covid-19 Vaccine Booster	23-04-13	DJ
SK Bioscience's Q4 Profit Plunges 85%	23-02-13	MT
South Korean Stocks Close Lower as Investors Look Forward to US CPI Data; SK Hynix Loses 3%	23-02-13	MT
SK Biopharmaceuticals Swings to Loss in Q4	23-02-09	MT
SK Bioscience to Establish Songdo Global Research & Process Development Center	23-02-08	CI
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs	23-01-27	CI